Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Father and son spending Christmas together after health scares - 2Dick Van Dyke shares his secrets to longevity as he turns 100
- 3Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- 4Drones, physics and rats: Studies show how the people of Rapa Nui made and moved the giant statues – and what caused the island’s deforestation
- 5The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Five killed in Israeli air strikes on tents near Khan Younis, medics say
- Exclusive new photos from 'Michael' biopic show Jaafar Jackson as King of Pop
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- Study reveals links between global food systems, obesity, and climate change
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- \Step by step instructions to Pick the Best Material Organization for Your Home\
- NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century
- True to life Authenticity d: A Survey of \Certifiable Stories\ Narrative
- HGV driver recruited others to smuggle migrants
